Product Information
TRI-MILI 28 TABLET is a generic product labeled by Aurobindo Pharma Limited, priced at $0.1264 per EA under NDC 65862077785. Its NADAC has been published 408 times since Dec 12, 2018.
FDA first approved this application on Jul 6, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Aurobindo Pharma LimitedNDC
65862077785
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205441FDA Approved
7/6/2016
TE Code
AB
On Market Since
7/6/2016
Price Statistics
The NADAC for TRI-MILI 28 TABLET has been published 408 times since Dec 12, 2018, and over the history we have for it it has declined 38.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1264 per EA |
|---|---|
| All-time high | $0.2207 (Jun 10, 2020) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1259 |
| Median price | $0.1495 |
| Average price | $0.1593 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 408 |
| Tracking since | Dec 12, 2018 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norgestimate and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-MILI 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-MILI 28 TABLET, manufactured by Aurobindo Pharma Limited, is $0.1264 per EA (NDC 65862077785), effective Sep 30, 2026.
How has the price of TRI-MILI 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-MILI 28 TABLET has declined 38.5%. It has been tracked across 408 weekly CMS publications since Dec 12, 2018.
What are the highest and lowest recorded NADAC prices for TRI-MILI 28 TABLET?
Since Dec 12, 2018, the NADAC for TRI-MILI 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2207 (Jun 10, 2020), with a median of $0.1495 per EA.
Are there cheaper alternatives to TRI-MILI 28 TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1080 per EA — about 15% below TRI-MILI 28 TABLET.
Who manufactures TRI-MILI 28 TABLET?
TRI-MILI 28 TABLET (NDC 65862077785) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.